Genetic alterations in ERBB2-amplified breast carcinomas - PubMed (original) (raw)
Affiliations
- PMID: 10632352
Comparative Study
Genetic alterations in ERBB2-amplified breast carcinomas
J Isola et al. Clin Cancer Res. 1999 Dec.
Abstract
Amplification of the ERBB2 oncogene has recently received attention as a target for antibody-based therapies and as a predictor of response to adjuvant chemotherapy. Modification of treatment strategies based on ERBB2 status has led to further interest in the genetic alterations that accompany ERBB2 gene amplification or overexpression. In this study, chromosome alterations that are associated with ERBB2 amplification were defined by comparative genomic hybridization (CGH). Additionally, fluorescence in situ hybridization (FISH) was used to validate gene amplification, and protein expression was detected immunohistochemically. ERBB2-amplified tumors as detected by FISH, immunohistochemistry (IHC), or CGH had twice as many CGH-defined chromosomal alterations (means of 11.8, 11.0, and 12.7, respectively) as the nonamplified tumors (means of 6.8, 7.0, and 5.6, respectively). ERBB2 positivity correlated with the total number of genetic events. A wide spectrum of copy number gains and losses was seen by CGH in all of the tumors. An increased number of losses of 18q and gains of 20q was found in ERBB2-positive tumors. Other common aberrations for all of the tumors were copy number gains of 1q (58%), 8q (52%), 20q (30%), and losses of 18q (39%), 13q (39%), and 3p (33%). A high degree of concordance was observed among the three methods in 33 primary breast cancers. The concurrence for ERBB2 detection between FISH and IHC was 90%, between FISH and CGH was 82%, and between IHC and CGH was 84%. This study shows that breast tumors showing erbB2 overexpression or gene amplification are genetically distinct from erbB2-negative tumors. These differences may relate to the mechanisms underlying altered response to adjuvant therapies and may define the responsiveness to erbB2-directed immunotherapy.
Similar articles
- Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K, Trojanec R, Kolár Z, Cwiertka K, Cernáková I, Mihál V, Hajdúch M. Bouchalová K, et al. Neoplasma. 2006;53(5):393-401. Neoplasma. 2006. PMID: 17013533 - Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C, Bellet M, Fabregat X, Serrano S, Solé F. Salido M, et al. Breast Cancer Res. 2005;7(2):R267-73. doi: 10.1186/bcr996. Epub 2005 Jan 26. Breast Cancer Res. 2005. PMID: 15743507 Free PMC article. - Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, Sastre-Garau X. Couturier J, et al. Mod Pathol. 2000 Nov;13(11):1238-43. doi: 10.1038/modpathol.3880228. Mod Pathol. 2000. PMID: 11106082 - [Cytogenetic abnormalities, genetic alterations, and applications for genetic diagnosis in breast cancer].
Tsukamoto K, Emi M, Nakamura Y. Tsukamoto K, et al. Nihon Rinsho. 1996 Dec;54(12):3389-97. Nihon Rinsho. 1996. PMID: 8976125 Review. Japanese. - [Current aspects of the evaluation of ERBB2 activation in breast cancer. Therapeutic perspectives].
Tse C, Brault D, Etienne J. Tse C, et al. Ann Biol Clin (Paris). 1997 Nov-Dec;55(6):545-54. Ann Biol Clin (Paris). 1997. PMID: 9499914 Review. French.
Cited by
- Reduced Basal Nitric Oxide Production Induces Precancerous Mammary Lesions via ERBB2 and TGFβ.
Ren G, Zheng X, Bommarito M, Metzger S, Walia Y, Letson J, Schroering A, Kalinoski A, Weaver D, Figy C, Yeung K, Furuta S. Ren G, et al. Sci Rep. 2019 Apr 30;9(1):6688. doi: 10.1038/s41598-019-43239-x. Sci Rep. 2019. PMID: 31040372 Free PMC article. - Development of NIST standard reference material 2373: Genomic DNA standards for HER2 measurements.
He HJ, Almeida JL, Lund SP, Steffen CR, Choquette S, Cole KD. He HJ, et al. Biomol Detect Quantif. 2016 Mar 9;8:1-8. doi: 10.1016/j.bdq.2016.02.001. eCollection 2016 Jun. Biomol Detect Quantif. 2016. PMID: 27335805 Free PMC article. - The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathways.
Guerram M, Jiang ZZ, Yousef BA, Hamdi AM, Hassan HM, Yuan ZQ, Luo HW, Zhu X, Zhang LY. Guerram M, et al. Oncotarget. 2015 Sep 8;6(26):21865-77. doi: 10.18632/oncotarget.4156. Oncotarget. 2015. PMID: 26068969 Free PMC article. - Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer.
Park SY, Seo AN, Jung HY, Gwak JM, Jung N, Cho NY, Kang GH. Park SY, et al. PLoS One. 2014 Jun 27;9(6):e100429. doi: 10.1371/journal.pone.0100429. eCollection 2014. PLoS One. 2014. PMID: 24971511 Free PMC article. - Amplification of HER2 is a marker for global genomic instability.
Ellsworth RE, Ellsworth DL, Patney HL, Deyarmin B, Love B, Hooke JA, Shriver CD. Ellsworth RE, et al. BMC Cancer. 2008 Oct 14;8:297. doi: 10.1186/1471-2407-8-297. BMC Cancer. 2008. PMID: 18854030 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous